CCM
LYRA

CAAS Capital Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

CAAS Capital Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-600
Closed -$340K – 556
2020
Q2 		$340K Buy
+600
New +$439K 0.01% 339

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAAS Capital Management's LYRA Position: Q3 2020 in Review

CAAS Capital Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2020, closing a stake of 600 shares — an estimated $340K sold.

CAAS Capital Management first reported a position in LYRA in Q2 2020 and held it in 1 quarter. The position peaked at $340K in Q2 2020. 40 funds tracked by Wall St. Rank hold LYRA as of Q3 2020.

  • CAAS Capital Management reported no remaining LYRA THERAPEUTICS INC position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 600 LYRA THERAPEUTICS INC shares in Q3 2020, an estimated $340K.
  • CAAS Capital Management first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's LYRA THERAPEUTICS INC position peaked at $340K in Q2 2020.
  • 40 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.